

Release Date: May 8th, 2006

Kenta Biotech Ltd. founded by Berna Biotech Ltd. (a Crucell Company) and private investors with the aim to discover and develop fully human monoclonal antibodies

Kenta Biotech Ltd., a spin-off from Berna Biotech Ltd (a Crucell company), has been founded. The new company is located at the Berna Biotech premises in Berne. Berna Biotech holds 36.74%, four independent private investors and the management together 63.26% of the Kenta Biotech share capital.

Kenta Biotech owns a unique technology platform to create fully human monoclonal antibodies which are expected to have substantial advantages over currently available monoclonal antibodies.

It is developing a portfolio of therapeutic monoclonal antibodies that are specifically designed to treat life-threatening hospital-acquired infections such as serious *Pseudomonas aeruginosa* or Staphylococcus aureus infections as well as other diseases.

The company has roughly 10 Mio CHF as capital available. This start-up capital will enable Kenta Biotech to advance its lead product, a monoclonal antibody against life-threatening *Pseudomonas aeruginosa* infections, into Phase II clinical trials. The first results in patients are expected beginning of next year. In addition, Kenta Biotech has several projects in preclinical phase. One of the key objectives of the new company will be to broaden the pipeline significantly within the next two years. To generate additional value, Kenta Biotech will also seek collaborations with partners that are already active in this therapeutic area.

The board of directors comprises Dr. Kuno Sommer (chairman), Dr. Peter Grogg , Hans-Beat Gürtler, Dr. Wieland Wolf, as well as Prof. Dr. Hans Hengartner . The board of directors has appointed Violetta Georgescu-Kyburz as Chief Executive Officer , Prof. Dr. Alois B. Lang as Chief Scientific Officer and Dr. Wolfgang Schuette as Chief Medical Officer of Kenta Biotech. They have a long-standing experience in the pharmaceutical industry as well as in the development and commercialisation of biotechnology products.

Currently, Kenta Biotech employs 14 highly qualified scientists and technical staff at its headquarters in Berne and is fully operational on international industry standards.

For additional information please visit our website www.kentabiotech.com or contact

Kenta Biotech Ltd
Violetta Georgescu-Kyburz, CEO
Rehhagstrasse 79
CH-3018 Berne
Tel.: +41 31 980 62 53
e-mail: info@kentabiotech.com